NASDAQ: SNTI - Senti Biosciences, Inc.

Altı ay boyunca karlılık: +0.5128%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Senti Biosciences, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

daha fazla ayrıntı
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2022-06-09
ISIN US81726A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sentibio.com
Цена ао 0.412
Günlük fiyat değişimi: -5.31% (4.14)
Haftalık fiyat değişimi: -1.26% (3.97)
Aylık fiyat değişimi: +83.18% (2.14)
3 ayda fiyat değişimi: +73.45% (2.26)
Altı ayda fiyat değişimi: +0.5128% (3.9)
Yıllık fiyat değişimi: +493.94% (0.66)
3 yılda fiyat değişimi: -60.32% (9.88)
5 yılda fiyat değişimi: 0% (3.92)
10 yılda fiyat değişimi: 0% (3.92)
Yılbaşından bu yana fiyat değişimi: +85.78% (2.11)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
EV/EBITDA -0.4243 0
Toplam: 5

Yeterlik

İsim Anlam Seviye
ROA, % -59.47 0
ROE, % -106.19 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.6122 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 2912.94 10
karlılık Ebitda, % 186.62 10
karlılık EPS, % 1244.77 10
Toplam: 10
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
NEA Management Company, LLC 4426151 9.67
8vc Gp I, LLC 2537558 5.55
ARK Investment Management, LLC 1969860 4.31
Vanguard Group Inc 707052 1.55
Intel Corporation 595665 1.3
Triatomic Management Lp 310533 0.68
Geode Capital Management, LLC 238406 0.52
Omega Fund Management, Llc 195792 0.43
Bridgeway Capital Management, Inc. 145000 0.32
Artal Group S.A. 55555 0.12



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 yıl)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 yıllar)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 yıl)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 yıllar)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

Adres: United States, South San Francisco. CA, 2 Corporate Drive - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.sentibio.com